[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Miedziowe Centrum Zdrowia SA\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":50},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":5},"100653438","glp-1gip-receptor-agonists-in-obesity-related-hfpef-the-glide-hf-registry-100653438",false,"NCT07787936","GLP-1\u002FGIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry","GLIDE-HF Registry: A Prospective, Single-Center, Observational Cohort of Patients With Obesity-Related Heart Failure With Preserved Ejection Fraction, With GLP-1\u002FGIP Receptor Agonist Therapy as an Observed Exposure and Serial Exercise Echocardiographic Phenotyping","GLIDE-HF","Inclusion Criteria:\n\nAge 18 years or older Body mass index (BMI) 30 kg\u002Fm2 or greater Symptomatic exertional dyspnea, fatigue, or reduced exercise tolerance Left ventricular ejection fraction 50% or greater Probable or established HFpEF per the diagnostic score algorithm (no low-probability result on either the H2FPEF or HFA-PEFF score) Able to perform semi-supine bicycle exercise echocardiography Written informed consent for registry participation and data processing\n\nExclusion Criteria:\n\nSignificant valvular heart disease Cardiomyopathy other than the typical HFpEF phenotype (suspected amyloidosis, restrictive or hypertrophic cardiomyopathy as the primary problem) Recent acute decompensated heart failure or recent hospitalization for heart failure Unstable coronary artery disease Severe pulmonary disease as the primary cause of dyspnea Severe anemia or another systemic cause of exercise limitation Inability to safely perform an exercise test Very poor echocardiographic window precluding any analysis Active malignancy or gynecological condition that may substantially affect CA-125 (diagnosed endometriosis, pelvic inflammatory disease, suspected ovarian tumor, significant non-cardiac ascites) Absence of consent for registry participation and data processing","ALL","18 Years",{"count":20,"type":21},150,"ESTIMATED","52 Weeks","OBSERVATIONAL","GLIDE-HF is a prospective, single-center, non-interventional observational cohort registry conducted within routine outpatient heart failure care at a cardiology clinic in Poland. It enrolls patients with obesity-related heart failure with preserved ejection fraction (HFpEF), defined by chronic heart failure symptoms or exertional dyspnea, body mass index at least 30 kg\u002Fm2, left ventricular ejection fraction at least 50%, and objective evidence of HFpEF using contemporary diagnostic scores (H2FPEF and HFA-PEFF), without a dominant alternative cause of dyspnea.\n\nThe registry's guiding principle is that all eligible obesity-related HFpEF patients are enrolled regardless of their treatment. Therapy with a glucagon-like peptide-1 (GLP-1) receptor agonist or a dual GLP-1\u002FGIP receptor agonist (for example semaglutide, tirzepatide, liraglutide, dulaglutide, or others) is an observed exposure, not an assigned intervention. All decisions about initiating, selecting, dosing, or modifying such therapy are made solely by the treating physician according to clinical, regulatory, and reimbursement indications, as part of standard care and independently of the registry. The protocol does not propose, allocate, or modify any pharmacological treatment, does not randomize, and does not create a protocol-defined control group. Patients not receiving such therapy serve as a naturally occurring observational comparator.\n\nThe scientific value of GLIDE-HF lies in deep mechanistic phenotyping rarely available in large-scale registries. The core assessment tool is serial exercise (stress) echocardiography, which allows direct evaluation of diastolic reserve during exercise, an abnormality that may be absent at rest and revealed only under load. This is complemented by lung ultrasound for pulmonary congestion (B-lines), left atrial and right ventricular strain analysis, a full iron and hepcidin panel, right ventricular-pulmonary artery coupling assessment, cardiac and congestion biomarkers (NT-proBNP, CA-125), quality of life (Kansas City Cardiomyopathy Questionnaire), and functional capacity (6-minute walk test). The identical assessment panel is applied to all enrolled patients regardless of treatment status, ensuring comparability between treated and untreated patients.\n\nObservation is embedded in the routine outpatient visit schedule, with assessment points at baseline and at 12, 24, and 52 weeks, and the possibility of continued follow-up. The registry characterizes trajectories of exercise diastolic reserve and accompanying mechanistic and clinical parameters over time in treated patients (primary axis), and explores comparisons between treated and untreated patients (secondary axis), with a methodological aim of assessing the feasibility of reliable serial exercise echocardiography and lung ultrasound in an unselected, real-world obesity-related HFpEF population, in whom obesity substantially complicates imaging.\n\nThe registry is descriptive and hypothesis-generating. Because of its observational design, all analyses relating to treatment effect are descriptive only and cannot be interpreted as evidence of a causal drug effect, given the absence of randomization, possible regression to the mean, and confounding by indication. Target enrollment is at least 150 patients, recruited continuously from January 2027. GLIDE-HF is a non-commercial study conducted under bioethics committee opinion and applicable data protection law.",[26,27,28,29,30],"Heart Failure With Preserved Ejection Fraction","Obesity","Diastolic Heart Failure","Pulmonary Hypertension","Iron Deficiency",[32,27,33,34,35,36,37],"HFpEF","GLP-1 receptor agonist","Semaglutide","Tirzepatide","stress echocardiography","Lung ultrasound","NOT_YET_RECRUITING","2026-08-23",{"date":41,"type":42},"2026-08-26","ACTUAL",{"date":44,"type":21},"2027-01-01",{"date":46,"type":21},"2033-01-01",{"name":48,"class":49},"Miedziowe Centrum Zdrowia SA","OTHER",""]